Figure H-1 displays the evidence network for the network meta-analysis for remission according to Disease Activity Score. The diagram graphically displays the number of studies that comprise the evidence base for the analysis and indicates the number of head-to-head and MTX-controlled studies underpinning the pairwise comparisons. The number of trials and participants for each comparison with MTX are as follows: Abatacept (1 trial, N=232), Abatacept plus MTX (2 trials, N=744), Adalimumab (1 trial, N=531), Adalimumab plus MTX (1 trial, N=525), Certolizumab plus MTX (1 trial, N=879), Etanercept plus MTX (1 trial, N=542), Infliximab plus MTX (3 trials, N=1,098), Methylprednisolone plus MTX (1 trial, N=29), Tocilizumab (2 trials, N=792), and Tocilizumab plus MTX (2 trials, N=1,084). The number of trials and participants for the head-to-head comparisons are as follows: Abatacept vs. Abatacept plus MTX (1 trial, N=235), Adalimumab vs. Adalimumab plus MTX (1 trial, N=542), Infliximab plus MTX vs. Methylprednisolone plus MTX (1 trial, N=30), and Tocilizumab vs. Tocilizumab plus MTX (2 trials, N=1,082).

Appendix Figure H-1Network diagram for network meta-analysis: Remission according to Disease Activity Score

MTX = methotrexate; N = number of patients

From: Appendix H, Supplementary Primary Network Meta-Analyses

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.